Elisabeth Linder
Former CEO and president of Diamyd, Lindner, is a director at BioInvent International AB and Karo Bio AB.
Also newly appointed at the firm is Anders Wiklund, who is now chairman of the board.
With the appointments in place for the firm’s next stage of development – its compounds Nefecon and Busulipo are under development – MD Johan Haggblad said: “We have two highly promising product candidates under evaluation.
“Anders's and Elisabeth's exceptional industry experience will be invaluable in ensuring we realize value for Pharmalink and for patients with significant unmet medical need."